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S U M M A R Y
Controlled clinical trials are essential tools for evaluating the efﬁcacy of antibiotic treatment against
infection, but the results of such trials critically depend on sensitive, reproducible, and feasible outcome
measures. We reviewed randomized controlled trials on the antibiotic treatment of diabetic foot
infection published between 1999 and 2009 in terms of quality and endpoints. Discrepancies in study
design, inclusion criteria, statistical methodology, and the varying deﬁnitions of both clinical and
microbiological endpoints between the published studies, make it difﬁcult to compare them, as well as to
determine which regimen may be the most appropriate for patients with diabetic foot infection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Randomized clinical trials (RCTs) are widely accepted as the
best way to obtain scientiﬁcally sound conclusions for evaluating a
new drug. To draw valid conclusions, the outcome measures must
be clearly deﬁned before initiation of the trial and need to be
objective, precise, and reproducible.1 Moreover close attention
must be paid to the training of investigators, especially in
multicenter trials.2 Results from studies based on poorly stan-
dardized procedures that use ambiguous deﬁnitions or are
conducted by insufﬁciently trained staff, can lead to both loss of
power and bias in the estimate of treatment effect.
Foot infection involving the skin and soft tissues and/or bony
structures, is a common and costly complication of foot ulcers in
diabetic individuals (hereafter, diabetic foot infections – DFI) and
represents a major cause of morbidity and mortality.3 DFI is
estimated to be the most common cause of diabetes-related
admission to hospital and remains one of the major pathways to
lower-limb amputation.4 Systemic antibiotic treatment must be
given as early as possible for DFI, initially on an empirical basis.
With regard to treatment, several guidelines are available based on* Corresponding author. Tel.: +33 466 668 286; fax: +33 466 668 914.
E-mail address: julien.crouzet@chu-nimes.fr (J. Crouzet).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.05.003the results of RCTs,4,5 but differences in methodology and
measurement of outcome make it difﬁcult to assess the actual
efﬁcacy of such treatments. The purpose of this study was to
analyze the overall quality of RCTs on antibiotic treatment of DFI
published between 1999 and 2009, with special attention to
clinical and microbiological endpoints.
2. Materials and methods
2.1. Search methods for identiﬁcation of studies
RCTs published between January 1999 and December 2009
were identiﬁed from two electronic databases: MEDLINE and The
Cochrane Library. Relevant studies were selected and reviewed for
collection of data. Additional studies were identiﬁed from the
reference lists of the retrieved papers. A combination of free text
and controlled vocabulary search terms was applied, including the
following terms: ‘diabetes mellitus’, ‘diabetes’, ‘diabetic foot
infection’, ‘infected diabetic ulcer’, ‘osteitis’; ‘osteomyelitis’, ‘skin
and soft tissue infections’, ‘linezolid’, ‘cephalosporins’, ‘penicillins’,
‘glycopeptides’, ‘carbapenems’, ‘ﬂuoroquinolones’, ‘randomized
controlled trial’, and ‘clinical trials’. There was no language
restriction. Abstracts of oral or poster presentations, as well as
reviews, were excluded.ses. Published by Elsevier Ltd. All rights reserved.
J. Crouzet et al. / International Journal of Infectious Diseases 15 (2011) e601–e610e6022.2. Inclusion and exclusion criteria
Publications were selected for inclusion if the outcome of DFI
management was clearly reported. Trials that involved both
inpatients and outpatients were eligible for analysis. The abstracts
of all identiﬁed citations were independently reviewed by two
members of the study team (JC, JPL) to determine if they met the
main eligibility criteria, i.e., RCT design, original data from an adult
population, focus on antibiotic treatment for DFI. Agreement for
inclusion in this review was reached by consensus. Each included
paper was then assessed by one of the two reviewers using a
custom-prepared data extraction sheet, including study design,
characteristics of patient populations, results of bacteriological
analysis, types of intervention, duration of follow-up, and types of
outcome measure (clinical, biological, microbiological, and radio-
logical). Items were rated as ‘done’, ‘not done’, or ‘not reported’. Co-
reviewers discussed the ﬁndings from the data extraction and the
methodological quality of each paper to reach a ﬁnal decision.
We regarded endpoints as clinical and/or bacteriological,
qualitative or quantitative variables that provided conclusive
evidence of a tangible beneﬁt for the patient. To be considered as
an endpoint, a variable had to be clearly stated as an objective of
the study. Endpoints were further classiﬁed into clinical and
microbiological. Results were reported as the percentage for
qualitative variables and as the mean value ( standard deviation)
for quantitative variables. Descriptive analysis was performed to
evaluate endpoints. As heterogeneity between studies in terms of
design, interventions, follow-up, and outcomes was evident when
analyzing extraction sheets, no attempt was made to pool the results.
3. Results
3.1. Study features and overall population enrolled
From 123 papers identiﬁed in the initial search, 14 studies met
the criteria for inclusion in the analysis, bringing together 3119
patients with DFI (Table 1).6–19 The main reasons for excluding
studies were that they were not randomized or not focused on
antibiotic treatment. Six of the included trials were double-blinded
studies,8,13,15–18 whereas six were open-label studies6,9–11,14,19
and two were single-blinded.7,12 All studies but two11,19 were
multicenter trials. Six were from multidisciplinary foot clinics; no
data about the patient setting was available for the other eight
studies. Only one study19 was clearly not supported by a
pharmaceutical company.
Eight of the RCTs (57.1%) were conducted speciﬁcally in diabetic
patients,10–14,16,18,19 while the remaining six involved both
diabetic and non-diabetic subjects.6–9,15,17
Deﬁnitions of severity of infection at inclusion were heteroge-
neous, ranging from mild to moderate (n = 2),13,18 to mild to severe
(n = 4),8–11 moderate to severe (n = 6),6,12,14–16,19 and severe
(n = 1);7 no information was available in one study.17 Wound
area and depth were measured and wound and surrounding skin
assessed at enrolment in 12 (85.7%) studies.8–19 However, wounds
were classiﬁed using a validated gradation system (University of
Texas classiﬁcation, Wagner gradation system, or the score from
Knighton et al. and modiﬁed by Pecoraro et al.) in only ﬁve (35.7%)
studies.6,13,14,18,19 Two studies used infection wound scores that
are not validated in the literature.8,9 The presence of osteomyelitis
was an exclusion criterion in all but two studies.10,19
Regarding co-morbidity, peripheral arterial disease (PAD), a
well-known unfavorable prognostic factor for diabetic foot ulcer
(DFU), was reported in some studies,10,11,13,14,19 but no clear
criteria for diagnosis were given. In some trials, patients were
excluded if they had critical limb ischaemia10,17,18 or PAD requiring
a revascularization procedure.13 No study reported data onglycemic control, except that of Clay et al.11 in which only the
capillary blood glucose level was measured.
There were only very few data about local wound care,
generally using vague terms like ‘proper’,13 ‘optimal’,19 or
‘appropriate’12,18 wound care. Wound debridement was some-
times mentioned,8,10,12–14,18 but only Lipsky et al.12,18 and Harkless
et al.14 reported that neuropathic wounds were off-loaded.
Duration of antibiotic treatment ranged from 4 days14 to 4
weeks,10,13,18 but data were unavailable in one study.12 In seven
studies (50.0%), treatment was administered for 7–14
days.6,8,9,12,15–17 All studies reported the duration of follow-up,
which ranged from 1 week to 2 months after the end of antibiotic
treatment.
Studies differed in the statistical methodology. Five trials were
designed to show superiority of the tested agent compared with
accepted standard treatment,6,10,11,16,19 ﬁve studies were designed
to show non-inferiority,12,13,15–17 and the remaining four studies
were designed to test equivalence between response rates in the
two treatment groups. In all trials with a superiority design, a non-
inferiority or an equivalence analysis was subsequently performed
because superiority was not demonstrated in any treatment group.
3.2. Microbiological results
All studies provided information concerning the organisms
cultured, and the method of obtaining this culture was described in
13 studies.6,8–19 Specimens were obtained using superﬁcial wound
swabs, wound curettage after debridement, needle aspiration of
purulent material, or tissue or bone biopsy, as appropriate. In 10
studies,8–10,12–16,18,19 swabbing of the wound was not allowed or
was discouraged in order to avoid contamination with superﬁcial
colonizing bacterial ﬂora that may not represent the causative
pathogens.
Bacterial pathogens isolated in all included studies are shown in
Table 2. Two studies were limited to Gram-positive bacterial
infections and consequently gave no data on the prevalence of
Gram-negative bacteria.6,12 Only one study clearly excluded
potentially colonizing bacteria, like coagulase-negative staphylo-
cocci or Corynebacterium spp.13 As described for most studies on
DFI, the most frequently isolated pathogen was Staphylococcus
aureus (6.5–48.8%). Enterobacteriaceae were the most commonly
cultured Gram-negative bacteria (7.0–33.7%). Pseudomonas aeru-
ginosa was isolated in only 2.5–14.6% of infected wounds. The
frequency of infection by multiple organisms was reported in nine
trials (64.3%)7,8,10,12–15,17,19 polymicrobial infection was observed
in 11.0–55.0% of cases with microbiological data.
3.3. Studies by type of antibiotic therapy
Ten trials investigated the use of ‘beta-lactam/beta-lactamase
inhibitor’ combinations (piperacillin–tazobactam, ticarcillin–tazo-
bactam, amoxicillin–clavulanate, ampicillin–sulbactam).7–11,13–
16,19 Carbapenems were used in three trials8,13,19 and ﬂuoroqui-
nolones in ﬁve.7,9,15,16,18 Amongst glycopeptides, vancomycin was
administered by discontinuous infusion in two studies12,17 and
teicoplanin was used in one study.6 In all studies, antibiotics were
used according to their usual dosage. Only one RCT compared
topical antibiotic treatment versus parenteral antibiotherapy.18
The most common treatment regimen employed in the studies was
intravenous treatment (n = 13, 92.8%). Intravenous treatment was
followed by oral therapy once the infection improved in 6 studies
(42.9%).7,9,10,13,15,16
In 10 studies, the antibiotic regimen was modiﬁed based on
culture and susceptibility results, whereas there was apparently no
change in one study.18 In the three other studies, the presence of a
pathogen known to be resistant to either of the study medications
Table 1
Characteristics of RCTs included in the study
Ref. Study designa Population Number of DP Male sex (%) Age (years) Diabetes duration
(years)
Wound severity Osteomyelitis at
baseline (%)
Treatment
duration (days)
Saltoglu19 OL, SC DP 64
33 vs. 31
62.5 vs. 63.3 58.7 (37–80) vs.
58.3 (47–72)
10.5 (0–30) vs.
13.5 (3–30)
12.5/59.4/28.1 vs.
16.7/50.0/33.3b
81.2 vs. 76.3 14 (28 for
osteomyelitis)
Lipsky18 c DB, MC DP 835
418 vs. 417
68.0 60 ND 7.0 vs. 7.2d Excluded 14–28
Noel17 c DB, MC DP (31%) and non-DP 257
168 vs. 89
63.0 vs. 64.0e 52.915.5 vs.
51.915.6e
ND 19 vs. 20e,f Excluded 7–14
Lipsky16 c DB, MC DP 127
63 vs. 64
71.4 vs. 71.9 57.011.8
57.512.5
ND Moderate-to-severe Excluded 7–14
Giordano15 c DB, MC DP (12%) and non-DP 78
37 vs. 41
66.0 vs. 65.0e 52.415.9 vs. 52.815.4)c ND Moderate-to-severe Excluded 7–14
Harkless14 c OL, MC DP 314g
155 vs. 159
57.3 vs. 42.7h 62.014.2 vs. 58.712.9h ND 0/58.3/13.5/27.1/1.0 vs.
0/56.2/21.3/21.3/1.1h,i
Excluded 4–14 (possibly
extended to 21
days)
Lipsky13 c DB, MC DP 586
295 vs. 291
61.0 vs. 68.0 59 (25–90) vs. 57 (22–94) ND 68.0/32.0 vs. 66.0/34.0j Excluded 5–28
Lipsky12 c SB, MC DP 103
47 vs. 56
54.0 vs. 54.0 60.0 vs. 63.0 ND Moderate-to-severe Excluded 7–14
Clay11 c OL, SC DP 70
36 vs. 34
100.0 vs. 100.0 6511.5 vs. 629.9 10.57.9 vs.
13.99.8
Mild-to-severe Excluded ND
Lipsky10 c OL, MC DP 361
241 vs. 120
71.0 vs. 72.0 6312 vs. 6213 ND Mild-to-severe 24.0 vs. 17.0 7–28
Graham9 c OL, MC DP (17%) and non-DP 67
36 vs. 31
63.0 vs. 58.8e 51.9 vs. 49.8e ND 82.5/17.5 vs. 77.4/22.6e,k Excluded 7–14
Graham8 c DB, MC DP (25%) and non-DP 98
53 vs. 45
66.1 vs. 63.9e 48.716.5 vs. 48.017.4e ND 82.1/17.9 vs. 82.7/17.3e,k Excluded 7–14
Siami7 c SB, MC DP (18%) and non-DP 76
42 vs. 34
71.4 vs. 72.4e 52.0 (18–86) vs. 54 (19–92)e ND Severe Excluded <14
Stevens6 c OL, MC DP (29%) and non-DP 83
51 vs. 32
75.0 51 ND Moderate-to-severel Excluded 7–14
RCT, randomized controlled trial; DP, diabetic patient; ND, not done.
For number of diabetic patients, male sex, age, diabetes duration, wound severity and osteomyelitis, data are experimental treatment vs. comparator.
a DB, double-blind; SB, single-blind; OL, open-label; MC, multicenter; SC, single center.
b Wagner class 2/3/4 (in %).
c Studies supported by a pharmaceutical company.
d Wound infection score (mean) (score from Knighton et al. as modiﬁed by Pecoraro et al.).
e Data in the whole population (DP and non-DP).
f Percentage of patients with systemic inﬂammatory response syndrome.
g Only 185 patients were clinically evaluable (96 vs. 89).
h In clinically evaluable population.
i University of Texas grade IB/ID/IIB/IID.
j University of Texas grade 0–I B–D (moderate)/II–III B–D (severe).
k Mild-to-moderate/severe infection (%).
l As assessed by a modiﬁed Wagner scale.
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Table 2
Pathogens isolated at baseline
Pathogens isolated (%) Stevens,6
1999a
(n=637)
Siami,7
2001b
(n=353)
Graham,8
2002b
(n=320)
Graham,9
2002b
(n=609)
Lipsky,10
2004
(n=400)
Clay,11
2004
(n=87)
Lipsky,12
2005a
(n=123)
Lipsky,13
2005
(n=714)
Harkless,14
2005
(n=273)
Giordano,15
2005b
(n=338)
Lipsky,16
2007
(n=111)
Noel,17
2008
(n=205)
Lipsky,18
2008
(n=1008)
Saltoglu,19
2009
(n=89)
Gram-pos aerobic cocci 100.0 69.7 65.3 48.4 71.3 86.0 100.0 41.6 74.7 65.4 71.2 58.5 77.3 42.7
Staphylococcus sp 67.0 39.4 35.3 25.9 46.3 59.0 45.5 NS NS NS NS NS 34.7 22.5
S. aureus 46.2 39.4 35.3 23.3 32.8 36.0 44.7 20.6 48.4 36.4 30.6 48.8 30.1 6.5
MSSA NS 32.3 32.8 22.2 26.5 NS 36.6 18.6 37.8 31.4 NS 36.1 NS NS
MRSA NS 7.1 2.5 1.1 6.3 NS 8.1 2.0 10.6 5.0 NS 12.7 NS NS
Streptococcus sp 29.4 19.8 15.0 19.4 12.3 16.0 31.7 6.4 17.6 20.1 27.0 9.8 17.9 8.9
Enterococcus sp 3.6 10.5 6.6 3.1 12.8 11.0 22.8 6.7 8.8 8.9 13.5 NS 24.6 11.2
Gram-pos aerobic bacilli NS NS NS 0.3 NS NS NS NS NS NS NS NS NS 0
Gram-neg aerobic bacilli NI 27.2 27.8 22.3 28.8 7.0 NI 16.5 15.0 15.1 16.2 41.5 21.2 50.6
Enterobacteriaceae NI 17.6 13.4 16.9 22.0 7.0 NI 10.1 10.3 15.1 9.0 33.7 13.6 32.6
Escherichia coli NI 4.8 2.5 5.2 NS NS NI NS 1.8 5.9 2.7 9.3 3.5 7.9
Proteus mirabilis NI 2.8 6.9 NS NS 7.0 NI NS 3.7 3.3 6.3 6.8 4.1 5.6
Stenotrophomonas maltophilia NI NS NS NS NS NS NI NS NS NS NS NS 1.9 0
Pseudomonas aeruginosa NI 9.6 4.1 2.5 6.8 NS NI 3.2 4.8 NS NS 7.8 5.8 14.6
Gram-pos anaerobic cocci NI NS 2.2 10.2 NS NS NI 19.0 NS 6.5 NS NS NS 0
Peptostreptococcus spp NI NS NS 8.7 NS NS NI 12.2 NS 6.5 4.5 NS NS 0
Gram-pos anaerobic bacilli NI NS NS 2.6 NS NS NI 5.9 NS NS NS NS NS 0
Gram-neg anaerobic bacilli NI 3.1 4.7 16.1 NS 7.0 NI 11.2 MS 13.0 8.1 NS NS 1.1
Bacteroides fragilis NI 3.1 NS 3.9 NS NS NI NS NS 5.6 1.8 NS 1.5 NS
Gram-neg anaerobic coccobacilli NI NS NS NS NS NS NI 5.7 NS NS NS NS NS 0
Polymicrobial infections NS 55.0 40.0 NS 30.5 NS 28.2 46.5 29.5 47.7 NS 11.0 NS 40.3
pos, positive; neg, negative; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; NS, not speciﬁed; NI, not included.
a Study included only infections caused by Gram-positive cocci.
b Data only available for foot infection in both the diabetic and non-diabetic population.
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Table 3
Endpoint criteria used in RCTs
Stevens,6
1999
Siami,7
2001
Graham,8
2002
Graham,9
2002
Lipsky,10
2004
Clay,11
2004
Lipsky,12
2005
Lipsky,13
2005
Harkless,14
2005
Giordano,15
2005
Lipsky,16
2007
Noel,17
2008
Lipsky,18
2008
Saltoglu,19
2009
Clinical outcome (clinical cure rate) a a a a a a a a a a a a a a
Clinical success b
Infection resolved or cured a a a a a a a a a a a a a
Improvement a a a a a a a a a
Clinical failure
Failure   a  a     a  a a a
Indeterminate – not evaluable  a a    a  a a
Recurrence/relapse  a 
Amputation       
Bacteriological outcome
(microbiological eradication rate)
a a          
Microbiological eradication a a          
Presumed eradication          
Persistence         
Presumed persistence    
Persistence with acquisition of resistance 
New pathogen at the same site     
Same pathogen at another site 
Another infection (urinary, pneumonia)
Not evaluable      
Evaluation time-points
Test-of-cure visit (time post-therapy) EOT 6–14
days
2–5
days
10–21
days
15–21
days
96 h after
initiation of
treatment
6–20
days
DCIV 14–21
days
10–42
days
10–42 days 7–14
days
EOT EOT
Long-term follow-up (time post-therapy) 1–4
weeks
21–35
days
3–4
weeks
21–35 days 20–28
days
10 days
after DCIV
2 weeks 2 months
Other assessment time-points Days 3, 5,
end of therapy
End of
therapy
(3 days after)
Day 5 Days 4, 7,
at end of
treatment
Time of
switch IV
to oral
therapy,
days 3–5
during therapy,
end of therapy
Time of switch
IV to oral
therapy, days
3–5 during
therapy, end
of therapy
Days 3,
10, 14, 21 after
enrollment
RCT, randomized controlled trial; EOT, end of treatment; DCIV, time of discontinuation of intravenous therapy; IV, intravenous.
Black dots indicate outcomes listed in the study protocol.
a Primary outcomes of each study.
b Treatment success was deﬁned by at least one of the following measures: body temperature<38.1 8C (100.6F), normalization of capillary blood sugar level, improvement of wound staging, and white blood cell count <10109/l.
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J. Crouzet et al. / International Journal of Infectious Diseases 15 (2011) e601–e610e606was an exclusion criterion.8,9,16 In eight studies, the use of
glycopeptides was allowed if methicillin-resistant S. aureus
(MRSA), methicillin-resistant Staphylococcus epidermidis, or peni-
cillin-resistant Enterococcus sp were identiﬁed or sus-
pected.7,10,11,13–16,19 In the case of the presence of Gram-
negative bacteria, patients received additional concomitant anti-
biotics (metronidazole, aztreonam) in six studies.10–12,15–17 In ﬁve
studies, patients were excluded if there was the need for any
additional concomitant antibiotic.6,7,9,12,14
3.4. Endpoint criteria
The criteria used to deﬁne endpoints are presented in Table 3. In
all studies, the primary efﬁcacy endpoint was the clinical response
rate, deﬁned as the proportion of patients in whom the infection
was considered clinically cured and/or improved at the test of cure
(TOC) visit.
In all studies, clinical response consisted of a change in signs
and symptoms of infection at the TOC visit relative to baseline
assessment. In four studies, the clinical response was deﬁned as
favorable only if clinical signs and symptoms were totally
resolved,7,8,10,19 whereas other studies9,12–18 included either
complete clinical resolution or improvement of infection in theTable 4
Clinical cure and microbiological eradication rates
Reference; antibiotic treatment 
Stevens, 19996
IV/IM teicoplanin (once daily 6 mg/kg then 3 mg/kg) 
Cefazolin (1.5–2 g/day to 2–3 g/day) 
Siami, 20017
IV clinaﬂoxacin (200 mg/12 h) then clinaﬂoxacin PO (200 mg/12 h) 
IV piperacillin–tazobactam (3.375 g/6 h), then amoxicillin–clavulanate PO (625 mg
Graham, 20028
IV ertapenem (1 g/day) 
IV piperacillin–tazobactam (3.375 g/6 h) 
Graham, 20029
IV levoﬂoxacin (750 mg/day) then levoﬂoxacin PO (750 mg/day) 
IV ticarcillin–clavulanate (3.1 g/4–6 h), then possibly amoxicillin–clavulanate (875
Lipsky, 200410
IV linezolid (600 mg/12 h) or linezolid PO (600 mg/12 h) 
IV ampicillin–sulbactam (1.5–3 g/6 h) or amoxicillin–clavulanate PO (625 mg/8 h o
Clay, 200411
IV metronidazole (1 g/day) plus IV ceftriaxone (1 g/day) 
IV ticarcillin–clavulanate (3.1 g/6 h) 
Lipsky, 200512
IV daptomycin (4 mg/kg/day) 
IV vancomycin (1 g/12 h) or IV semi-synthetic penicillin (4–12 g/day) 
Lipsky, 200513
IV ertapenem (1 g/day) then amoxicillin–clavulanate PO (1 g/12h) 
IV piperacillin–tazobactam (3.375 g/6 h), then amoxicillin–clavulanate PO (1 g/12 
Harkless, 200514
IV piperacillin–tazobactam (4.5 g/8 h) 
IV ampicillin–sulbactam (3 g/6 h) 
Giordano, 200515
IV moxiﬂoxacin (400 mg/day) then moxiﬂoxacin PO (400 mg/day) 
IV piperacillin–tazobactam (3.375 g/6 h), then amoxicillin–clavulanate PO (625 mg
Lipsky, 200716
IV moxiﬂoxacin (400 mg/day) then moxiﬂoxacin PO (400 mg/day) 
IV piperacillin–tazobactam (3.375 g/6 h) then amoxicillin–clavulanate PO (800 mg
Noel, 200817
IV ceftobiprole (500 mg/8 h) 
IV vancomycin (1 g/12 h) plus IV ceftazidime (1 g/8 h) 
Lipsky, 200818
Pexiganan cream (2 applications/day) 
Oﬂoxacin (200 mg/12 h) 
Saltoglu, 200919
IV piperacillin–tazobactam (4.5 g/8 h) 
IV imipenem–cilastatin (0.5 g/6 h) 
IV, intravenous; IM, intramuscular; PO, per os; ND, not done.
a Rate in both diabetic and non-diabetic patients.same deﬁnition. In the study by Lipsky et al.,10 clinical success was
deﬁned not only by complete resolution of baseline signs and
symptoms of infection, but also with a healing wound. On the other
hand, Clay et al.11 deﬁned treatment success as clinical stability or
an improvement of infection mainly based on changes in systemic
signs (body temperature, blood sugar level, white blood cell
count); Stevens6 gave no clear deﬁnition of ‘clinical success’. A
scoring system was used in only four studies,13,14,18,19 providing a
more objective evaluation of the outcome.
In contrast, clinical failure was deﬁned in many different ways
in the reviewed studies. Deﬁnitions included ‘failure’ if there was
persistence or progression of signs and symptoms of infection
while on treatment, ‘insufﬁcient resolution’ requiring additional or
alternative antibiotic treatment, ‘recurrence’ or ‘relapse’ if there
was worsening after discontinuation of antibiotic treatment, and
‘requirement for surgical intervention’. Amputation was consid-
ered as a clinical failure endpoint in only six studies,7,8,13,14,17,19 as
a reason for exclusion of patients from the ‘per-protocol’ analysis in
four studies,6,9,15,18 and was not considered in four studies.10–12,16
Among all studies, the response to therapy was not evaluated at
the same time in the follow-up period. In most studies, evaluation
was assessed at a time interval varying from 2 to 42 days after
completing the study drug.7–9,11,12,14–17 In other trials, evaluationClinical cure (%) Microbiological
eradication (%)
86.0 89.9a
91.0 85.0a
51.7 43.8
/8 h) 48.0 31.9
65.7 83.2a
70.9 86.0a
69.2 83.7a
 mg/12 h) 57.1 71.4a
81.3 ND
r 1 g/12 h) 71.3 ND
72.2 ND
76.5 ND
66.0 64.4
70.0 56.9
71.3 93.2
h) 65.9 80.7
81.3 78.5
83.1 73.3
67.6 81.0a
/8 h) 60.9 81.0a
67.6 69.0
/12 h) 61.0 66.0
86.2 79.5
81.8 78.0
86.8 47.1
90.4 47.3
46.7 95.8
28.1 96.0
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few studies there was no precise time of evaluation.6,19
Clinical success rates (Table 4) varied widely, ranging from 28%
to 91% in both the investigational and control arms.
Another endpoint often used in DFI studies is the microbiolog-
ical eradication rate. The microbiological success rate, deﬁned as
the percentage of proven or presumed eradicated baseline
pathogens, is reported in Table 4. This endpoint was lacking in
two studies10,11 and varied from 32% to 96% according to the type
of experimental agent and comparator.
Information dealing with treatment success in DFI patients was
provided by all trials included in the analysis. In addition,
according to the data provided by the 14 trials, there was no
signiﬁcant difference between the compared groups regarding the
microbiological eradication rate. Moreover, clinical cure rates were
often higher than microbiological eradication rates. Finally, we
summarized important key issues in RCTs on antibiotic therapy of
diabetic foot infection (Table 5)33–35.
4. Discussion
Over the past 10 years, much progress has been made in the
management of DFI, however there are no standardized guidelines
for the deﬁnition of a DFI clinical trials endpoint. Generally
speaking, deﬁning success in clinical trials on DFUs remains
problematic, and more meaningful outcomes or endpoints must be
determined, as recently emphasized by the Los Angeles DFCon
consensus.20 Regarding DFI, our report underlines the great inter-
study variability in terms of design, selection criteria, duration of
treatment, clinical and microbiological endpoints, and statistical
analysis. With the exception of one study, all of the studies19 we
analyzed were supported by pharmaceutical companies, which
probably inﬂuenced the design, statistical analysis, and endpoint
deﬁnition; this could also partly explain the heterogeneity
between studies, carried out according to the sponsor’s aims.
Concerning the design, it should be noted that nearly half of the
studies were open-label trials; this could potentially induce a
signiﬁcant bias for interpreting results. A crucial problem in
assessing the results of the studies was the difference in severity of
infection and the lack of objective and validated criteria for
deﬁning the seriousness of the infectious process in many studies.
Speciﬁc data that would allow an assessment of the extent of DFI
were lacking in six studies,6,7,10–12,15 while eight studies8,9,13,14,16–
19 did provide them but used four different grading systems.
Severity of infection was objectively graded in only one study using
a wound infection score18 that was validated in a later publica-
tion;21 this scoring system, based on severity of signs and
symptoms of infection in combination with measurements of
wound size and depth, has been shown to be predictive of the
clinical response rate.21,22 A major advance in the ﬁeld was the
development of a classiﬁcation scheme for infection severity by the
International Working Group on the Diabetic Foot23 and the
Infectious Diseases Society of America (IWGDF/IDSA).4 This
IWGDF/IDSA scheme, endorsed by the French-speaking Society
for Infectious Diseases,5 was recently validated by Lavery et al.,24
who showed that there was a statistically signiﬁcant trend
between increased risk for lower limb amputation, higher level
of amputation, and hospitalization with increasing infection
severity as deﬁned by this classiﬁcation system. The usefulness
of the IWGDF/IDSA guidelines with regard to microbiology and the
costs of DFI was also recently shown in our own department.25 As
the severity of infection deeply affects the clinical outcome, it is
mandatory to assess wounds of the same degree of severity in
order to compare the efﬁcacy of antibiotic agents: for that purpose,
the IWGDF/IDSA grading system or the DFI wound scoring system
would be a useful tool. Osteomyelitis was most often considered anexclusion criterion, but not in all studies. As osteomyelitis
represents a special entity among DFIs due to difﬁculties in its
deﬁnition, diagnosis, and management,4 inclusion of such patients
could affect the outcome and make it difﬁcult to compare results
between trials. Finally, the presence of signiﬁcant peripheral
arterial disease (PAD) excluded patients in some RCTs,11,15,18,19
however the combination of infection and PAD has recently been
shown to be frequent26 and associated with a very poor outcome.27
The usual doses of antibiotics were used in all included trials.
However, the duration of treatment varied markedly, from 4 to 28
days. In studies including osteomyelitis, the antibiotic duration
was shorter than that recommended by the IDSA guidelines.
The main problems in DFI trials are related to the clinical
outcome. First, the time-period over which to assess the clinical
response varied widely, from just after the discontinuation of
therapy to 6 weeks after the treatment was completed. Second, the
deﬁnition of success and failure differed among studies: in most
trials, clinical success included complete resolution or improve-
ment of signs and symptoms of infection, without the need for
additional antimicrobial therapy. Other studies used a more
conservative deﬁnition, with partial resolution being considered as
a failure.7,19 At the other end of the spectrum, Clay et al.11 deﬁned a
treatment success as ‘clinical stability’. Moreover, terms such as
‘cure’, ‘improvement’, ‘eradication’, ‘failure’, and ‘recurrence’ were
not used with the same meaning by all of the authors. Finally, ‘non-
evaluable patients’ were considered as failures in some studies, but
were not taken into account in the statistical analysis in others:
this may be problematic, as such patients may account for up to
40% of the randomized population.15–17 From a microbiological
point of view, the criteria for success were more consistent across
studies, deﬁned as actual or presumed eradication; however it was
not always clear whether patients with no microbiological
assessment at the test of cure visit were considered microbiologi-
cally evaluable (as presumed eradication or persistence) or not. As
for clinical efﬁcacy, the number of patients who were not evaluable
for microbiological efﬁcacy was also problematic, amounting to up
to half of the enrolled patients in some studies.7,10 A potential
reason for microbiological non-evaluability appears to be the
absence of pathogen in the baseline culture.7,10While S. aureus was
by far the most commonly isolated pathogen at baseline in all
studies, there was a wide variation in the frequency of other
pathogens, in particular of anaerobes and P. aeruginosa. This may
be due in part to differences in sample collection and culture
techniques. While national and international guidelines strongly
recommend that the specimen is obtained by needle aspiration or
from tissue deep in the wound,4,5,28 superﬁcial swabbing was used
in some studies,6,7,11 with the potential risk of contamination by
the superﬁcial colonizing bacterial ﬂora. The isolation of non-
pathogenic colonizing bacteria may also explain why no difference
in microbiological eradication rate was observed between broad-
spectrum antibacterials and agents with a more restricted
bactericidal spectrum. The impossibility of differentiating causa-
tive pathogens from harmless commensal bacteria colonizing the
wound introduces a strong bias in the interpretation of results.
Nevertheless, studies in which a swabbing technique was used
were included in our review because this technique remains
widely used and some argue that swabbing can give adequate
results.6,11,17 We recently proposed that the use of oligonucleotide
arrays or simple polymerase chain reaction analysis could help
discriminate colonization from infection due to S. aureus in DFUs
and contribute to a more adequate use of antibiotics:29 it is likely
that development of this new technology will contribute to an
improvement in the quality of RCTs. We also found that
measurement of inﬂammatory markers, especially C-reactive
protein and procalcitonin, would be of interest to differentiate
infected from non-infected DFIs.30 It is surprising that none of the
Table 5
Key issues (based on previous clinical trial results) in RCTs on antibiotic therapy of diabetic foot infection
Key issue Proposals
Design of the study  Preferably double-blind; if not possible, single (investigator)-blinded
 Method of randomization must be detailed, as well as allocation concealment
 Superiority preferable to non-inferiority trial (if non-inferiority trial, potential advantages
(cost, side effects, ease of administration) of the new drug must be explored)
 ITT approach in superiority trial, per-protocol and ITT analyses for non-inferiority triala
Population  Adult diabetic patients (according to American Diabetes Association)
 Therapeutic compliance as well as organ failure that may interfere with antibiotic prescription
must be considered before enrolment
Criteria for infection  Chronic (duration 3 weeks) inframalleolar foot wound with clinically diagnosed infection
 Separate OM from SSTIs
 For SSTIs, use IWGDF/IDSA classiﬁcation system (and/or eight-item DFI wound score21) to
diagnose infection and grade its severity
 For OM, use IWGDF criteria for diagnosis33
Previous antibiotic therapy  Exclusion of patients who have received antibiotic therapy for >24 h within 3 days prior to study enrolment
Presence of limb ischemia  Patients with PAD must be included except those with critical limb ischemia and/or requiring
a revascularization procedure
 PAD preferably diagnosed by a non-invasive test (ABPI or systolic toe pressure)
Specimen for culture  When? Within 24 h of initiating treatment with the study drugs
 How? By tissue biopsy, wound curettage, ﬁne-needle aspiration; no swabbing
Restrictions on pathogens (e.g., which
were eliminated or selected-for);
deﬁnition of pathogen
 Deﬁne pathogens as any bacteria isolated from microbiological sample other than those considered as
part of colonizing bacterial ﬂora (Corynebacterium, Propionibacterium, Bacillus spp, coagulase-negative
staphylococci), unless one of these species is isolated in pure culture
 Pathogens considered as colonizers if organisms other than the original pathogens appear in a setting
of clinical resolution
 Patient with MRSA, Pseudomonas aeruginosa, or Enterococcus could be withdrawn from the study because
of antimicrobial resistance
Baseline assessment  Assessment of the wound (area, depth)
 Assessment of glycemic control (HbA1c)
 Assessment of arterial status (ABPI or toe pressure)
 Assessment of the severity of infection
 Measurement of inﬂammatory marker such as CRP level
 PEDIS classiﬁcation system34 is a potentially useful tool for such assessments
Local wound care  Adequate wound care must be delivered including debridement, off-loading, and dressing (American
Diabetes Association guidelines)
 Use of antiseptics not permitted
 Non-adherent dressings not containing antibacterial products (like silver-based or antibiotic-impregnated
dressings) should be used
 Exclusion of surgical procedure considered to be deﬁnitive therapy (amputation)
Treatment duration  At least 7 days, possibly extended to 28 days for SSTIs
Other antimicrobial products
(topical or systemic) allowed?
 Exclude patients who need concomitant systemic or topical antibiotic therapy (even if it is treatment for
another infection)35
Outcome deﬁnitions  Clinical outcome must be the primary endpoint (it is a clinical trial!); microbiological outcome should be
a secondary endpoint
 Time to outcome:
- At EOT, within 3 days of the EOT
- At the FUA, within 7–15 days after completion of the study
 Clinical outcomes:
- Clinical success should be deﬁned as either ‘cure’ or ‘improvement’
Cure: complete regression of symptoms and signs of infection relative to baseline assessment
Improvement: complete regression of most but not all symptoms and signs of infection or sufﬁcient
improvement such that no further antibiotic therapy is needed
- Clinical failure should be deﬁned as one of the following:
Failure: persistence or progression of most of the pre-therapy symptoms and signs of infection
Relapse or recurrence: patients who respond at ﬁrst but whose symptoms and signs worsen after the
completion of treatment
The need for further antibiotic treatment after completion of the study, whatever the reason, or surgical
non-planned procedure due to foot infection
Evaluation of patients impossible
 Microbiological outcomes:
- Favorable response:
Complete eradication of all microorganisms present before treatment
Partial eradication if at least one but not all of the initial pathogens are eradicated and no additional
pathogens are isolated
Presumptive eradication if the patient has a clinical success but no sample is available for culture
- Failure or persistence: if more than one of the initial pathogens is recovered, whatever the clinical outcome, or
if only one pathogen is recovered but associated with a clinical failure
 Other endpoints to be considered:
Progression of wound infection score
Change in level of circulating inﬂammatory markers
Safety (adverse events)
Costs
ITT, intention-to-treat; OM, osteomyelitis; SSTI, skin and soft tissue infection; IWGDF/IDSA, International Working Group on the Diabetic Foot/Infectious Diseases Society of
America; DFI, diabetic foot infection; PAD, peripheral arterial disease; MRSA, methicillin-resistant Staphylococcus aureus; ABPI, ankle brachial pressure index; HbA1c, glycated
hemoglobin; CRP, C-reactive protein; EOT, end of therapy; FUA, follow-up assessment.
a For more details on non-inferiority randomized trials, see Piaggio et al.35
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exception of the study by Noel et al. in which a C-reactive protein
higher than 50 mg/l was considered as a criterion for severity of
infection.17
The last point that deserves discussion deals with the statistical
analysis. The method of randomization, allocation methodology,
and concealment were infrequently reported.7,11,13,17,19 Most
analyses were based on the intention-to-treat (ITT) population,
except in two studies in which a ‘per-protocol’ analysis was carried
out6,19; nevertheless, the ITT population was often an ‘efﬁcacy-
valid’ population according to the criteria used by some of the
authors. On the other hand, most of the RCTs we reviewed were
powered for testing the non-inferiority hypothesis or equivalence.
However, these types of study should satisfy certain points to be
valid: (1) reliable and reproducible evidence of the effect of the
control regimen compared with no speciﬁc therapy must be
evident from historical studies; (2) the planned non-inferiority
trial must conform as closely as possible to the design of the
studies that showed the effect of the control regimen in terms of
disease deﬁnition, study populations, concomitant medication,
and endpoint deﬁnitions and timing; and (3) the selected margin of
potential inferiority of the test intervention compared with the
control intervention must be precisely deﬁned.31 This last point is
the main limitation of such a design, because it supposes a degree
of tolerable inferiority of the new drug compared with the standard
treatment. This arbitrary difference (or delta) should be deﬁned
before performing the study. Non-inferiority is established when
the point estimate and 95% conﬁdence interval of the effect of the
new drug do not fall outside the preset non-inferiority limit. By
consequence, a non-inferior test drug could be less effective than
the comparator. Since 2001, the US Food and Drug Administration
(FDA) and the European regulatory authorities have raised
concerns on this subject and have recommended that study
results must show that there is a 95% probability that the true cure
rate for the new drug is no more than 10% lower than the cure rate
for the approved drug. This recommendation is responsible for an
increase in trial size and higher costs, and has probably contributed
to the small number of RCTs on infection conducted by the
pharmaceutical companies. Moreover, some authors have recently
suggested that non-inferiority trials have failed to meet the
commitments of good clinical research, disregarding patient
interests in favor of commercial ones.32 Indeed, the value of delta
remains the subject of debate between drug companies and
scientiﬁc committees, while current policy accepts this approach.
5. Conclusions
For all the reasons addressed in this paper, and considering the
heterogeneity of studies on antimicrobial strategies in DFI, the
currently used clinical endpoints are very heterogeneous. The
variability among recently published DFI trials and the absence of
important data are evident, such as the use of a wound score
classiﬁcation at entry into the study and at end of treatment, a
deﬁnition of infection severity, the antibiotic therapy treatment
duration and the follow-up period, and the absence of consider-
ation for concomitant treatment and local wound care. While
knowledge of the bacterial population in DFI is of interest at the
initiation of care, the microbiological eradication rate is an
endpoint more open to criticism in DFI management. The varying
deﬁnitions of infection severity and clinical endpoint that have
been used, highlight the need to develop a consensus classiﬁcation
system in order to improve the quality and comparability of DFI
trials. Further studies are required to offer standardized endpoint
deﬁnitions and uniform guidelines for future studies.
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